Abingdon Health
plc
("Abingdon" or "the Company")
Notice of
Results
Investor
Presentation
York, U.K. 4 October
2024: Abingdon Health plc (AIM:
ABDX), a leading international lateral flow contract research (CRO)
and contract development and manufacturing organisation
(CDMO), announces that it expects to
release its preliminary results for the year ended 30 June 2024 on
Tuesday 8 October.
Investor Presentation
The Company will provide a live
presentation relating to the preliminary results via the Investor
Meet Company platform on Tuesday 8 October at 9.30am
BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am the
day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Abingdon Health plc
via:
https://www.investormeetcompany.com/abingdon-health-plc/register-investor
Investors who already follow
Abingdon Health plc on the Investor Meet Company platform will
automatically be invited.
Enquiries:
|
Abingdon Health plc
|
www.abingdonhealth.com/investors/
|
|
Chris
Yates, Chief Executive
Officer
|
Via
Walbrook PR
|
|
Chris
Hand, Non-Executive Chairman
|
|
|
|
|
|
Zeus Capital (Sole Broker and Nominated
Adviser)
|
Tel:
+44 (0)20 3829 5000
|
|
Chris Fielding / Isaac
Hooper (Corporate Finance)
|
|
|
Fraser Marshall (Corporate
Broking)
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations)
|
Tel: +44 (0)20 7933
8780 or abingdon@walbrookpr.com
|
|
Paul McManus / Alice
Woodings
|
Mob: +44 (0)7980 541
893 / +44 (0)7407 804 654
|
|
Phillip Marriage
|
+44 (0)7867 984
082
|
|
|
| |
About Abingdon
Health plc
Abingdon Health Group is a leading
med-tech contract service provider offering its services to an
international customer base.
The Company's
CDMO division offers lateral flow product
development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays
or transfer existing laboratory-based assays to a lateral flow
format. Abingdon Health's CDMO division has the internal
capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing, including companion
diagnostics, animal health and environmental testing, from initial
concept through to routine and large-scale manufacturing; from
"idea to commercial success".
Abingdon's regulatory services
companies,
Compliance Solutions (Life Sciences) and
IVDeology, provide a broad range of regulatory
services to the in vitro diagnostic and wider medical device
industry, to support customers in bringing products to market
across a range of territories including the USA, EU and the UK. Our
consultancy services range from design, implementation and
maintenance of quality management systems, preparation of technical
files for regulatory approvals, part-time and interim management
support, auditing both internal and external, management reviews
and presentations, training and mentoring.
Abingdon Health's Abingdon Simply Test range of
self-tests is an e-commerce platform that offers a range of
self-tests to empowers consumers to manage their own health and
wellbeing. The
Abingdon Simply Test e-commerce site offers
consumers a range of information to support them in making informed
decisions on the tests available. In addition, the site provides
Abingdon's contract services customers with a potential route to
market for self-tests. The Abingdon Simply Test range is also sold
through international distributors and through other channels in
the UK and Ireland, such as pharmacy chains.
Founded in 2008, Abingdon Health is
headquartered in York, England.
For more information
visit: www.abingdonhealth.com